Positive Outlook for Arcturus Therapeutics: Promising mRNA Technology and Competitive Edge in Urea-Cycle Disorders

Thomas Shrader, an analyst from BTIG, maintained the Buy rating on Arcturus Therapeutics (ARCT – Research Report). The associated price target remains the same with $48.00.

Thomas Shrader has given his Buy rating due to a combination of factors that highlight the potential of Arcturus Therapeutics’ mRNA technology. The recent data from their liver-focused pipeline, particularly the ARCT-810 readout, shows promising results in treating urea-cycle disorders. Patients demonstrated significant improvements, moving from symptomatic to asymptomatic states, which suggests the treatment’s effectiveness in increasing relative urea cycle function (RUF) to levels that alleviate symptoms.
Moreover, the competitive landscape for treating these disorders is evolving, with Arcturus’ approach offering a dosable alternative to gene therapy, which may not provide lasting effects for all patients. The company’s focus on mRNA purity and the flexibility in dosing positions them well against competitors. Additionally, the use of a new assay to measure urea cycle function precisely adds credibility to their results, potentially paving the way for future regulatory approval. These factors contribute to the positive outlook and the Buy rating for Arcturus Therapeutics.